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ABSTRACT 
Purpose: To assess the improvement in swallowing status, overall survival and treatment 
related complications in patients with Carcinoma of the Oesophagus treated with palliative 
radiotherapy. 
 
Methods: A retrospective analysis of patients with advanced squamous cell carcinoma of 
the oesophagus who were treated for palliation from May 2007 to June 2012 at the 
Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) was done. Ninety- nine 
patients received palliative radiation therapy during this period, 63% were male and 37% 
female with a mean age of 60, 6 years. The predominant site of lesion was middle 3rd 
(56%) and 86, 9% of patients had lesions more than 5cm in length. Patients received 
palliative External beam irradiation (EBRT) with or without High dose rate brachytherapy 
(HDRBT) as per the CMJAH, Department of Radiation Oncology protocol. 
 
Results: There was an overall significant improvement in swallowing status (p<0,001). 
Eighty –four patients (85%) had an improvement in swallowing score after treatment.  
The effect of treatment was not significant in the relationship between the change in 
swallowing status and treatment group. Overall mean time to progression was 3, 7 months. 
The median overall survival was 7, 7 months. The type of treatment did not affect survival 
significantly, unadjusted (p=0, 31) or adjusted for prognostic parameters (age, sex, length 
of lesion, site of lesion, and pre-treatment swallowing status) (p=0.29). There were 
treatment related complications in 32% of cases, consisting of ulcerations (24%), tracheo- 
oesophageal fistula (5%) and strictures (3%). 
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Conclusion: In patients with advanced squamous cell oesophageal carcinoma, palliative 
radiotherapy is an effective modality in improving a patient’s dysphagia and thus quality of 
life. 
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NOMENCLATURE 
 
AIDS                                                               Acquired immune deficiency syndrome  
 
AP-PA                                                             Antero-posterior, postero-anterior fields 
 
CMJAH                                                           Charlotte Maxeke Johannesburg Academic  
                                                                         Hospital  
 
EBRT                                                              External Beam Radiotherapy  
 
ECOG                                                              Eastern Cooperative Oncology Group 
 
Gy                                                                    Gray (unit of radiation) 
 
HDRBT                                                           High dose rate brachytherapy  
 
HIV                                                                  Human immunodeficiency virus  
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1. INTRODUCTION AND LITERATURE REVIEW 
1.1 Introduction 
 
Oesophageal carcinoma is a highly lethal malignancy, and is the sixth most common 
malignancy worldwide in males, and eleventh in females.1  
 
In South Africa there is a high incidence of oesophageal cancer and it ranks fourth in males 
and sixth in females.2     
 
Men are more commonly seen with oesophageal cancer than women and squamous cell 
carcinomas are the most common histological type.3 
 
The major risk factors accounting for more than 80% of cases are alcohol and tobacco use. 
Other factors include diets with minimal fruits and vegetables which are associated with an 
increase in squamous cell carcinoma.4, 5 
 
The most common presenting symptom of oesophageal cancer is dysphagia, which may 
progress rapidly to a stage where patients are unable to swallow even liquids and saliva. 
Dysphagia makes them prone to nutritional compromise and aspiration pneumonia.6 
 
Oesophageal cancer has a poor prognosis because the majority of patients present in a poor 
general condition and with advanced disease, where curative options are limited.7 In 
addition, the oesophagus has a rich lymphatic and vascular supply, hence local invasion 
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and early metastasis are common in newly diagnosed patients.8   A median survival time of 
2, 5 to 9, 9 months has been reported in patients with advanced oesophageal cancer.9 
  
The main aim of treatment remains palliation of dysphagia, to improve a patient’s quality 
of life.10 Various treatment modalities for palliation have been used in an attempt to relieve 
dysphagia and improve quality of life. These include surgery (bypass, resection), 
dilatation, chemotherapy, intubation, external beam radiotherapy (EBRT) and intraluminal 
brachytherapy.11 A combination of the aforementioned modalities has been reported to 
only marginally improve the results in advanced cases.  
 
The administration of intraluminal brachytherapy allows a rapid tumour reduction of the 
luminal aspects, thereby restoring swallowing quickly. An added advantage of 
brachytherapy is the rapid falloff of dose, which decreases the risk of injury to the 
surrounding normal tissues.12,13   Previous studies have identified high dose rate 
intraluminal brachytherapy as an efficient and safe monotherapy, where palliation is the 
primary concern.7,9,10  
 
The use of EBRT is an effective and non – invasive modality, however a reported 
disadvantage was that relief of dysphagia occurred over a period of 4-6 weeks.14  
 
At the Charlotte Maxeke Johannesburg Academic Hospital (CMJAH), Department of 
Radiation Oncology a combination of palliative EBRT dose schedules with or with 
HDRBT are used to improve the swallowing status and quality of life in patients with 
advanced / non-operable oesophageal carcinoma.  
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1.2 Literature Review 
 
The review has been grouped into prospective and retrospective studies. 
 
1.2.1 Prospective Studies 
Amdel C et al. (2013) reported on a prospective study that included 41 patients at the 
Norwegian Radium Hospital with advanced oesophageal cancer. Their aim was to assess 
whether a combination of self – expanding metal stent (SEMS) and brachytherapy 
provided more rapid and prolonged effect on dysphagia without increased pain compared 
to brachytherapy alone. Patients were randomised to SEMS followed by brachytherapy, 
24Gy in 3 fractions of 8Gy each or brachytherapy alone. Patients that received SEMS 
followed by brachytherapy had a significantly improved dysphagia at 3 weeks post 
treatment compared to patients who received brachytherapy alone (p=0,02). At 7 weeks 
post treatment patients in both arms had less dysphagia. The authors concluded that for the 
relief of dysphagia, SEMS followed by brachytherapy is a preferable and safe method in 
patients for immediate alleviation. They also concluded that brachytherapy with or without 
preceding SEMS provides relief within a few weeks after treatment.15       
 
Homs MYV. et al. (2004) reported on a prospective multicentre randomised trial that 
compared the outcomes of brachytherapy and stent placement in patients with oesophageal 
cancer. Between December 1999 and June 2002, 209 patients from 9 hospitals in the 
Netherlands with advanced oesophageal or oesophagogastric junction carcinoma were 
randomised to stent placement (n=101) or single dose 12Gy HDRBT (n=101) and were 
followed up after treatment. It was found that dysphagia improved more rapidly after stent 
placement than after brachytherapy, however long-term relief of dysphagia was better after 
brachytherapy. More complications were seen with stent placement than brachytherapy 
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(36% vs 21%; p=0, 02). The authors recommended that HDRBT be used as primary 
modality for treatment of palliation of dysphagia from oesophageal carcinoma.16  
 
Taal BG et al. (1996) reported on a prospective trial of 74 patients from the Netherlands 
Cancer Institute with advanced inoperable oesophageal cancer. Patients were treated 
between February 1991 and September 1994 with a combination of a single dose HDRBT 
10Gy followed by 40Gy in 20 fractions EBRT which started 2 weeks after HDRBT. The 
aim of this study was to assess how quickly relief of dysphagia occurs in these patients. 
This study showed that brachytherapy improved dysphagia in 39% of the patients in a few 
days and achieved improvement in 70% of the patients at the end of treatment. Acute side 
effects occurred in 42% and late effects with ulceration in 7% of the patients after a median 
time of 4 months. The authors recommended that HDRBT prior to the administration of 
EBRT was a safe and effective modality to induce a rapid relief of dysphagia especially 
when combined with EBRT.17 
 
1.2.2 Studies done in South Africa or included South Africa  
Rosenblatt et.al. (2010) prospectively randomised 219 patients from six countries (Sudan 
=73; South Africa = 66; India = 29; Croatia = 20; China = 16; Brazil = 15) with squamous 
cell carcinoma of the oesophagus in order to determine whether the addition of EBRT to 
high dose – rate brachytherapy (HDRBT) is superior to HDRBT alone for the palliation of 
oesophageal cancer. Patients in that study were treated from March 2003 to June 2006. 
Each HDRBT consisted of 8Gy prescribed at 1cm from the active dwell positions, using 
equal dwell times, with the treatment length including the tumour plus a 2cm margin at 
both ends. The EBRT consisted of 30Gy in 10 fractions. The dysphagia relief experience 
was 82, 7% for combined therapy. The median overall survival was 188 days with an 18% 
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survival rate at 1 year.  The authors had concluded that the addition of EBRT to standard 
HDRBT improved symptoms and the combination is well tolerated and relatively safe.11 
 
Sur RK. et. al. (2002) prospectively compared two high dose rate brachytherapy 
fractionation regimens in the treatment of patients with surgically inoperable squamous 
cell oesophageal carcinomas between September 1996 and August 1999 at CMJAH. That 
study included 232 patients who were treated with either HDRBT of 16Gy given in 2 
alternate fractions of 8Gy each (Group A) or HDRBT of 18Gy given in 3 fractions on 
alternate days of 6Gy each (Group B). Dysphagia scoring was done according to the 
Mellow and Pinkas scoring system with 0 = able to swallow normal diet; 1= able to 
swallow some solid foods; 2 = able to swallow any semi-solid foods; 3 = able to swallow 
liquids only; 4 = unable to swallow anything / total dysphagia.  
The dysphagia – free survival for the whole group was 7, 1 months (Group A, 7.8 months; 
Group B, 6, 3 months; p>0, 05). Overall survival was 7, 9 months. The incidence of 
strictures (Group A, n=12; Group B, n=13; p>0, 05) and fistulas (Group A, n=11; Group B, 
n=12; p>0, 05) was similar in both groups.18 The authors concluded that fractionated 
HDRBT alone was an effective method for palliating patients with advanced oesophageal 
cancers. Both types of fractionation modalities yielded similar dysphagia- free survival, 
overall survival, toxicities and were equally effective as a palliation modality for advanced 
oesophageal cancer.  
 
Sur RK et al. (1998), reported on a prospective randomised trial of 172 patients with 
advanced oesophageal cancer at CMJAH. The aim of this study was to assess the 
optimised dose of fractionated HDRBT in the palliation of advanced oesophageal cancer. 
Patients were randomised to 3 Groups, Group A (12Gy in 2 fractions); Group B (16Gy in 2 
6 
  
 
 
fractions) and Group C (18Gy in 3 fractions). Overall survival was 19, 4% at the end of 12 
months for the whole group. The dysphagia – free survival was 28, 9% at 12 months for 
the whole group. The authors concluded that fractionated HDRBT was the best modality 
for palliation of advanced oesophageal cancer. The optimal dose ranged between 16Gy in 2 
fractions and 18Gy in 3 fractions given 1 week apart.10  
 
 
1.2.3 Retrospective Studies 
Murray JL et al. (2012) reported on a retrospective study that included 148 patients with 
inoperable oesophageal cancer. Patients were treated between 2005 and 2010 with 
palliative EBRT. The dose ranged between 20Gy to 30Gy were 89% of the patients 
(n=132) received a dose of 20Gy in 5 fractions. An improvement in dysphagia was seen in 
75% of the patients and the median overall survival was 6, 1 months. The authors 
concluded that EBRT remained an effective, non-invasive well tolerated modality to 
palliate dysphagia in selected patients.19     
 
Homs M. et al. (2003) reported on a retrospective study which included 149 patients from 
Netherlands treated with HDRBT only for inoperable oesophageal cancer, between 
January 1990 to December 1999 in order to assess the outcome of HDRBT alone in 
patients with malignant dysphagia. Patients were treated with a median dose of 15Gy in 
one or two sessions. Six weeks after HDRBT there was a statistical improvement of 
dysphagia score in 51% of the patients. Late complications of fistula formation or bleeding 
occurred in 7% of the patients (n=11). Median survival was 160 days with a 1 year survival 
rate of 15%. At follow up (median of 3 months), 37% of the patients experienced recurrent 
dysphagia.  
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The authors concluded that HDRBT is a moderately effective treatment for the palliation 
of malignant dysphagia. Early major complications were low, however persistent and 
recurrent dysphagia occurred frequently.20  
 
Sharma V. et al. (2002), reported on a retrospective study which included 58 patients from 
Tata Memorial Hospital with advanced/recurrent oesophageal cancer. Treatment consisted 
of HDRBT with or without EBRT from November 1994 to May 2000 to assess the 
improvement in swallowing status, complication rate and overall survival. All patients 
received two fractions of HDRBT of 6Gy per fraction one week apart, and 35% of the 
patients received a combination of EBRT and HDRBT. The EBRT dose was either 20Gy 
in 5 fractions or 30Gy in 10 fractions. There was an overall improvement in swallowing 
status in 22 patients (48%) and 24 (41%) maintained pre – treatment swallowing status. 
The median dysphagia – free survival was 10 months and the overall complication rate was 
30%. Median overall survival was reported for the entire group as 7 months. The authors 
concluded that HDRBT afforded patients with advanced/recurrent oesophageal good 
palliation with acceptable complications.9  
 
Hujala K et al. (2002) reported on a retrospective study that included 40 patients from 
Turku University Central Hospital (Finland) with inoperable oesophageal cancer, to assess 
if a combination of EBRT and HDRBT would increase local control. Patients were treated 
between 1989 and 1999, with EBRT 40Gy in 20 fractions and a week later HDRBT 10Gy 
in 4 fractions. Dysphagia could be relieved in 40% of the patients immediately and in most 
cases the progression of the disease could be delayed as evidenced by post – treatment 
serial endoscopy. The 1 and 2 year survival rates were 30 and 17, 5% respectively. The 
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authors concluded that HDRBT is a safe and efficient treatment modality to palliate 
patients advanced oesophageal cancer.21  
 
Brewster AE et al. (1995) reported on a retrospective study that included 197 patients from 
Christie Hospital in the United Kingdom who presented with advanced oesophageal 
carcinoma. Patients were treated between June 1988 and June 1992 with a single HDRBT 
fraction, the dose ranged from 7, 5Gy to 20Gy. This study showed an improvement in 
dysphagia in 54% of the patients.22  
 
The above prospective and retrospective studies from various countries have made no 
reference to patient characteristics in terms of risk factors for oesophageal cancer.   
 
Although the number of South Africans infected with HIV has increased by 2.17 million 
since 2002, when 4.02 million South Africans were living with the virus, none of the local 
studies above have taken HIV into consideration.  
 
At Charlotte Maxeke Johannesburg Academic Hospital (CMJAH), approximately 100 -150 
new cases of oesophageal cancer are seen in the Department of Radiation Oncology every 
year, and more than 85% of those patients are in an advanced stage with dysphagia as the 
main complaint.23   
 
Different treatment schedules have been suggested in the literature, and the choice of 
treatment is guided by the patient’s age, performance status and site of lesion.    
 
9 
  
 
 
The information obtained in this report would be of value to the Oncologists at CMJAH, in 
guiding them when choosing a treatment regimen, to palliate dysphagia in advanced/ non -
resectable oesophageal carcinoma. 
 
 
1.3 Aims of the study 
 
      1.3.1 The primary aim of this study was: 
     To assess the improvement in swallowing in patients of advanced carcinoma   
     oesophagus who received different palliative radiation treatments, controlling  
     for prognostic parameters (age, sex, length of lesion, site of lesion, and pre- 
     treatment swallowing status). 
 
      1.3.2 The secondary aims of the study were to asses: 
a) The variation in time to progression between treatment groups, controlling 
for the prognostic factors listed above 
b) The variation in overall survival between treatment groups, controlling for 
the prognostic factors listed above 
c) The variation in treatment related complications between treatment groups 
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2. METHOD 
 
This was a retrospective single institution study. Patients with advanced oesophageal 
cancer were treated with palliative radiation at the Charlotte Maxeke Johannesburg 
Academic Hospital, between May 2007 and June 2012 so that a follow up of 12 months is 
available in the records. 
 
The patient inclusion criteria included: 
1. Carcinoma of the oesophagus unsuited for radical radiation and curative surgery. 
2. Histologically proven squamous cell carcinoma of the oesophagus. 
3. Any length of lesion in the oesophagus. 
4. With or without metastatic disease. 
Exclusion criteria included: 
1.  Adenocarcinoma histology 
2. Previous radiation treatment 
 
The treatment protocol used in the Department of Radiation Oncology at CMJAH for 
palliative radiotherapy during the period between May 2007 and June 2012 was either 
external beam radiotherapy or a combination of external beam radiation and fractionated 
high dose brachytherapy. 
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2.1 Technique of EBRT and treatment dose  
Patients were X-ray simulated in the supine position, with their arms at the side. Barium 
was given as contrast at the time of simulation to delineate the length of tumour as a filling 
defect. Antero-posterior, postero – anterior fields (AP-PA) were used to administer either 
20Gy in 5 fractions in 1 week or 30Gy in 10 fractions over 2 weeks to the mid-line, and 
with upper and lower fields to be 3cm proximal and distal from the tumour limits and 
laterally to cover the pleural reflection. The energy used was either Cobalt 60 or 6 MV. 
The treatment schedule used depended on the treatment length and the performance status 
of the patient. If the treatment length was less than 12 cm and / or if the patient was in a 
poor performance status then the shorter treatment schedule was used (20Gy in 5 fractions 
in 1 week). If the treatment length was more than 12 cm and / or if the patient was in a 
good performance status then the longer treatment schedule was used (30Gy in 10 fractions 
in 2 weeks).   
 
2.2 Technique of HDRBT and treatment dose  
The patient swallowed barium at simulation and the field was placed to include the area of 
interest. The skin marking isocenter (SMIC) was then tattooed, and the films taken at the 
simulator were used in the brachytherapy procedure. The simulator procedure also serves 
to screen for a tracheo-oesophageal fistula (TOF), which is a contraindication to 
brachytherapy, and is most common in mid-third lesions.  A stent can be used if there is a 
fistula. The patients’ were starved overnight and Pethidine 50mg and maxolon 20mg were 
given intramuscularly one hour prior to the procedure. The patient lies supine and the 
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SMIC tattoo was marked with a wire. Xylocaine was sprayed into the patient's throat to 
anaesthetise the pharynx. As no barium was used in the procedure, there is no risk of 
aspiration. The doctor stands at the patient's right side, and his index finger is placed just 
above the patient's epiglottis, before passing the jellied oesophagus catheter to this level, 
anterior to his finger. The catheter is thus prevented from touching the pharyngeal wall to 
prevent gagging.  The patient is then asked to swallow and the epiglottis moves over the 
trachea, and the tube passes down the oesophagus. A 4mm and a 6mm catheter is available. 
The patient tends to bite on the tube, thus damaging it hence the equipment comes with a 
bite block which slips over the tube, and is held in place by a simple mask, to prevent the 
biting of the tube. The commonly used tube diameter at our centre is 6mm. A dummy 
source catheter is inserted into the tube and the tube fixed in the area of interest (tumour) 
under fluoroscopic guidance. With the oesophagus tubes, no transfer tube is required, as 
the distal end of the tube fits into the unit. The source offset and the treatment length must 
be clearly communicated to the treating radiographer. The treatment time is set according 
to the length of the treatment area and the dose to be given. 
Patients receive two sessions of HDRBT, 7 days apart. The total dose is 16Gy given in 2 
fractions. A dose of 8Gy is prescribed at 1cm from the central axis, and a margin of 2cm is 
given proximally and distally to the visible tumour (as already known from the simulator 
film). The prescription can either be optimised or non-optimised depending on the site of 
the lesion. 
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Figure 2.2.1 Equipment used for HDRBT  
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2.3 Data collection 
Case notes from patient files were reviewed to obtain information pertaining to pre-
treatment and post – treatment dysphagia, duration of any response, toxicities and survival.  
The protocol within the Department of Radiation Oncology at CMJAH during the period 
(May2007- June 2012) was to review patients 6 weeks post treatment and then every 3 
months thereafter. The data was recorded on the specially designed proforma for this 
study. (Appendix 1) 
 
Dysphagia was scored according to the system described by Mellow and Pinkas (1985) 
with 0 = able to swallow normal diet; 1= able to swallow some solid foods; 2= able to 
swallow any semi-solid foods; 3= able to swallow liquids only; 4= unable to swallow 
anything / total dysphagia.24   
 
2.4 Data analysis 
Statistical analysis was carried out using SAS software version 9.3 for Windows.25  
The overall change in swallowing status was assessed by the paired sample t-test. The 
relationship between the change in swallowing status and treatment group, and each of the 
prognostic parameters (age, sex, length of lesion, site of lesion, and pre-treatment 
swallowing status) was determined by a General Linear Model.  Post-hoc tests were 
conducted using the Tukey-Kramer tests, due to unequal treatment group sizes.  
Overall survival was determined from the day of first treatment to the last day of follow up 
or death using Kaplan – Meier analysis.  The relationship between the survival and 
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treatment group and each of the prognostic parameters was determined by a Cox 
proportional hazards model. 
The X2 test was used to assess the relationships between categorical variables. Fisher’s 
exact test was used for 2x2 tables or where the requirements for X2 test could not be met. 
The strength of the associations was measured by Cramer’s V and the phi coefficient 
respectively. 
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3. RESULTS 
3.1 Clinical Characteristics 
Data from the records of 99 patients that fitted the inclusion criteria were collected for this 
study. The mean age of patients was 60.6 years (range: 40-83 years), 63% were male and 
37% female. The overall performance status of the sample was divided between ECOG 1 
(18%), ECOG 2(34%) and ECOG 3(48%).  The pre – treatment dysphagia scores were 
either 2 (44%) or 3 (56%) as shown in table 3.1. 
 
 
TABLE 3.1 Patient Characteristics 
  Frequency 
(n=99) 
Percentage of 
total sample 
Age 40-49y 14 14.1 
50-59y 31 31.3 
60-69y 37 37.4 
70y+ 17 17.2 
Sex Male 62 62.6 
Female 37 37.4 
Site of lesion Upper third 1 1.0 
Middle third 55 55.6 
Lower third 21 21.2 
Upper & middle 7 7.1 
Middle & lower 15 15.2 
Length of lesion <5 cm 8 8.1 
5-10 cm 86 86.9 
>10 cm 5 5.1 
Dysphagia score 
PRE 
0 0 0.0 
1 0 0.0 
2 44 44.4 
3 55 55.6 
4 0 0.0 
        ECOG 1 17 18 
 2 33 34 
 3 47 48 
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3.1.1 Site distribution of lesions 
 
Figure 3.1 illustrates that the predominant site of lesions were in the middle third (56%). 
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3.1.2 Length of lesion 
The predominant lesion length was in the range of 5-10cm (87%) (Figure 3.2). 
 
 
 
 
3.1.3 Distribution of treatment schedules 
The frequency distribution (Figure 3.3), of the different treatments show that the 
distribution of patients between the treatment groups is variable. The number of patients 
that received 30Gy in 10 fractions EBRT (n=7) and 20Gy in 5 fractions EBRT (n=3) were 
very small in comparison to the other treatment arms which were: 16Gy in 2 fractions 
HDRBT alone, 30 Gy in 10 fractions EBRT with HDRBT, or 20Gy in 5 fractions EBRT 
with HDRBT). This makes inference about these groups very difficult.  
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3.1.4 Correlation between age and treatment group 
As illustrated in Figure 3.4, there was a significant association between age and treatment 
group (X2 test; p=0, 0023; Cramer’s V=0, 28). The use of 30Gy in 10 fractions EBRT plus 
HDRBT 16Gy in 2 fractions was lower for older patients, while 16Gy in 2 fractions 
HDRBT tended to be used more for older patients. The use of a shorter palliative 
radiotherapy regimen is decided by the treating Radiation Oncologist at the time of patient 
assessment based on performance and clinical status of the patient.   
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3.2 Swallowing Status 
There was an overall significant improvement in swallowing status (paired sample t-test; 
p<0.001). Eighty five percent (n=84) of the patients had an improvement in swallowing 
score of 1 or more points after treatment.  
 
Univariate analysis showed that the effect of treatment was not significant (p=0, 06), in the 
relationship between swallowing status and treatment group (Table3.2). 
 However, in the multivariate model, the effect of treatment group controlling for all the 
covariates was significant (p=0,041).  
 
TABLE 3.2 Relationship between Swallowing and Treatment Regimen 
Variable Univariate Multivariate 
p-value p-value 
Treatment group 0.060 0.041 
Age 0.092 0.30 
Sex 0.033 0.021 
Site 0.013 0.002 
Length 0.16 0.11 
Dysphagia score (PRE) 0.058 0.41 
 
Post – hoc tests using the Tukey-Kramer adjustment for unequal group sizes showed that 
the change in swallowing status was less effective for the use of 20Gy in 5 fractions EBRT 
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as compared with the use of 20Gy in 5 fractions EBRT plus HDRBT 16Gy in 2 fractions, 
30Gy in 10 fractions EBRT plus HDRBT 16Gy in 2 fractions, and 30Gy in 10 fractions 
EBRT. Given the small patient numbers in the 20Gy in 5 fractions EBRT treatment group 
(n=3) and 30Gy in 10 fractions EBRT group (n=7), this conclusion cannot be generalised.  
There were no other significant, between-group differences in change in swallowing status.   
The results are depicted in Figure 3.5 
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3.3 Dysphagia Relapse 
The overall mean time to dysphagia was 3, 7 months for 46% of the patients.  (Figure 3.6).  
 
 
Figure 3.6  
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3.4 Survival  
The median survival time was 7, 7 months and an estimated 33, 9% surviving to 12 months 
(Figure 3.7) (Table 3.3).  
Figure 3.7 Survival Curve 
 
 
 
 
Table 3.3 Survival Times 
           Overall (n=99) 
 
estimate 95% CI 
Actual data Median survival time (months) 7.7 (5.8-11.2) 
Percentage surviving to 12 
months 
33.9 (20.9-46.9) 
Max. survival time Median survival time (months) 20.4 (9.7-40.6) 
Percentage surviving to 12 
months 
57.6 (47.8-67.4) 
Min. survival time Median survival time (months) 3.2 (2.5-4.4) 
Percentage surviving to 12 
months 
13.1 (6.4-19.8) 
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To determine the effect of bias due to loss to follow-up, maximum and minimum survival 
rates were determined: 
To determine the maximal survival rate, it was assumed that patients who were lost to 
follow-up are alive at the end of the study which ended on 4/12/2013. The median survival 
time was estimated as 20, 4 months and 57, 6% surviving to 12 months   (Table 3.3) 
(Figure 3.8). 
 
 
Figure 3.8 Maximum Survival  
 
 
 
 
The minimum survival rate was determined by assuming that all patients lost to follow up 
died at the last follow up date. The median survival time was 3, 2 months and 13, 1% 
surviving to 12 months (Table 3.3) (Figure 3.9). 
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Figure 3.9 Minimum Survival 
 
 
 
 
The figures seen in the maximal and minimal survival times are extremes. If follow up of 
patients was aggressive, the figures between the actual data, maximum and minimal could 
actually be somewhere in the middle. 
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The relationship between the survival group and treatment group and each of the covariates 
in turn was determined by Cox proportional hazards model. The below graph (Figure 3.10) 
illustrates that the longest median survival time was obtained by the 30Gy in 10 fractions 
EBRT and HDRBT group of patients.  
 
 
 
 
 
Figure 3.10 Relationship between Survival Group and Treatment Group  
 
 
 
 
 
16Gy/2#/2w/ILBT 
20Gy/5#/1w/EBRT 
30Gy/10#/EBRT   
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As illustrated in Table 3.4 below, we see that the effect of treatment on univariate analysis 
was not significant for survival (p=0, 31). The results of the multivariate model, which 
considers the simultaneous influence of the prognostic factors, show that there were no 
significant differences in the survival curve between treatment groups (p=0, 29) 
 
 
 
TABLE 3.4 Relationship between Survival and Treatment Groups 
Variable Univariate Multivariate 
p-value p-value 
Treatment group 0.31 0.29 
Age 0.44 0.30 
Sex 0.36 0.22 
Site 0.51 0.44 
Length 0.58 0.55 
Dysphagia score (PRE) 0.46 0.52 
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3.5 Complications 
 
Treatment complications were recorded in 32% of the cases. The complications were 
divided between ulcerations (24%), tracheal oesophageal fistula (5%), and stricture (3%) 
(Figure 3.11).  
 
                                   Figure 3.11 Complications arising from treatment  
 
 
 
 
 
 
 
 
 
 
 
0
10
20
30
40
50
60
70
80
Stricture Ulceration T.O.F. None reported
P
e
rc
e
n
ta
ge
 o
f 
p
at
e
in
ts
29 
  
 
 
 
Figure 3.12 Relationship between Treatment Group and Complications  
 
 
 
 
 
There was no significant association between treatment group and treatment related 
complications (Fisher’s exact test; p=0, 12), (Figure 3.12) 
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4. DISCUSSION 
 
At CMJAH, Department of Radiation Oncology, approximately 100-150 new cases of 
oesophageal cancer are seen every year, with more than 85% of those patients having 
advanced oesophageal cancer.23 Dysphagia is a distressing symptom in advanced 
oesophageal cancer, and is the main complaint in 80% of the patients.6   Palliation of 
dysphagia is the major goal in the treatment of advanced oesophageal cancer, however 
there is no consensus on the best approach to achieve this goal. The protocol being  
followed at CMJAH is to offer patients palliative EBRT with or without HDRBT 
depending on the patients clinical condition. Poor follow up of the patients that received 
palliative radiotherapy at CMJAH make it difficult to assess treatment response, therefore 
the aim of this study was to assess improvement in swallowing status of patients that 
received palliative radiotherapy for advanced oesophageal carcinoma. The information 
obtained in this study can help guide the clinician in choosing the optimal palliative 
radiotherapy regimen to relieve symptoms and reduce suffering caused by cancer.  
 
From the data collected in the 99 patients it can be noted from Table 3.1, the patients were 
of advanced age as the mean age was 60,6 years and majority of the patients were between 
an intermediate (ECOG 2: 34%) and poor (ECOG3: 48%) performance status. The 
predominant lesion length in Figure 3.2 was in the range of 5-10cm (87%). The above data 
confirms and correlates with the literature that majority of patients are diagnosed with 
locally advanced oesophageal cancer and are clinically unwell due to poor nutrition from 
their dysphagia at the time of assessment.23 The different treatment regimens namely 30Gy 
in 10 fractions EBRT only, 20Gy in 5 fractions EBRT only, 30Gy in 10 fractions EBRT 
plus 16Gy in 2 fractions HDRBT, 20Gy in 5 fractions EBRT plus 16Gy in 2 fractions or 
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HDRBT alone 16Gy in 2 fractions were allocated to the above patients at the time of initial 
assessment based on the expert opinion of the individual treating radiation oncologist. As 
shown in Figure 3.3 and Figure 3.4 the shorter radiation treatment schedules: 30Gy in 10 
fractions EBRT only, 20Gy in 5 fractions EBRT only and 16Gy in 2 fractions HDRBT 
only, were allocated to older patients as they would not tolerate a longer course of 
treatment due to their clinical status, as well would be a burden with their short life 
expectancy and quick relief of their dysphagia would be the aim.   
 
Studies in the literature have shown that EBRT with or without HDRBT is an effective 
palliative treatment modality in advanced oesophageal carcinoma.9,10,11,18 Dysphagia in 
those studies were scored according to Mellow and Pinkas, were 0=able to swallow normal 
diet, 2=able to swallow any semi-solid foods, 3=able to swallow liquids only and 4= 
unable to swallow anything.24 An improvement in swallowing status was measured by 
assessing the post-treatment dysphagia score to the pre-treatment dysphagia score, a 
positive change in one or more points of dysphagia was an improvement.       
In this study the same dysphagia scoring system was also used. From the data collected in 
the 99 patients it was noted in Table 3.1 that the pre-treatment dysphagia scores were either 
2 (44%) or 3 (56%), which correlates with the literature that majority of patients with 
advanced oesophageal cancer have dysphagia as their main complaint. This study had 
shown that 85% (n=84) of the patients had an improvement in swallowing score of 1 or 
more points after treatment with palliative radiation and overall had an improvement in 
swallowing status (p<0.001). The results obtained in this study were comparable to that 
reported in the literature (Table 4.1).  
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Table 4.1 Swallowing Response Rates 
AUTHORS PATIENT NUMBERS TREATMENT IMPROVEMENT IN 
SWALLOWING 
STATUS 
Rosenblatt et al. 
(2010) 
110 EBRT + HDRBT 82,7% 
(p=0.019) 
 109 HDRBT  66,7% 
No p value stated 
Sur RK et al. (2002) 232 HDRBT 80% 
No p value stated  
Taal BG et al. (1996) 74 EBRT + HDRBT 70% 
No p value stated 
Murray JL et al. (2012) 148 EBRT 75% 
No p value stated  
Present Study 99 EBRT +/- HDRBT 85% 
(p=<0.0001) 
  
 
However due to the limitations of a retrospective study, and the small patient numbers in 
the 30Gy in 10 fractions EBRT and 20Gy in 5 fractions EBRT treatment groups, a specific 
treatment regimen could not be identified that statistically improved the swallowing status 
(Table 3.2 and Figure 3.5). Further studies with larger patient numbers per treatment arm 
are recommended.  
 
Patient survival reported in the literature range from 5 – 9, 9 months (Table 4.2).   
Table 4.2 Patient Survival 
AUTHORS MEDIAN SURVIVAL  ONE YEAR O.S. 
Murray JL et al. (2012) 6,1 months Not Reported 
Rosenblatt et al. (2010) 7 months 18% 
Homs et al (2003) 5,3 months 15% 
Sur RK et al. (2002) 6,2 months Not Reported 
Hujala et al. (2002) Not Reported 30% 
         Present Study 7,7 months 33,9% 
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In this study the median overall survival was 7, 7 months and an estimated 33, 9% 
surviving to 12 months. Although the result obtained are comparable to that seen in the 
literature, caution should be noted in the interpretation of the median survival time and the 
estimated surviving patients at 12 months in this study. The maximum and minimal 
survival rates as previously stated (Table 3.3) are very different to those of the actual data. 
This implies bias to patients who are lost to follow up and to those whom the date of death 
is unrecorded, which plays a large role in this data set. 
 
The dysphagia free survival reported in the literature ranges from 7 – 12 months for EBRT 
with or without HDRBT.9,11,18  In this study the overall mean time to dysphagia relapse was 
short at 3, 7 months for 44% of the patients that were recorded. The possible reasons for 
the short time in this study could be that only 44% of the patient population was recorded, 
or using the shorter radiation treatment schedules could have decreased the duration of 
palliation.  
 
As reported in the literature, palliative EBRT with or without HDRBT is a safe modality in 
the management of advanced non-operable oesophageal carcinoma.7,9,10,11,17 In this study 
detailed reporting of toxicity was not possible as sufficient detail was provided in only 
32% of the cases (Figure 3.12).  
 
Limitations were encountered in this study, many of which are common to any 
retrospective analysis such as small sample size per treatment group, poor patient follow 
up and poor record keeping in patient files.  
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In the proforma (Appendix 1) attached there were many variables that we hoped to have 
collected such as prognostic factors for survival (Weight loss, laboratory assessment and 
histological grade) and risk factors for disease such as social habits (smoking, alcohol) and 
HIV status. Unfortunately due to poor record keeping the above information could not be 
attained and analysed.    
 
However, within those limitations, the results of the current study revealed that palliative 
radiotherapy in patients with incurable oesophageal cancer provided an improvement in 
dysphagia in 84% of the treated patients. 
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5. CONCLUSION  
In this retrospective pattern of care analysis of patients with advanced oesophageal cancer, 
it was found that palliative radiotherapy is an effective modality in improving a patient’s 
dysphagia, despite the limitations encountered. 
 
Clinicians should choose a treatment regimen for a patient that is tailored to their age, 
performance status and extent of disease. 
 
It is recommended that further studies with larger sample sizes per treatment group are 
needed to address the role of a specific treatment regimen on improving swallowing status, 
the dysphagia free survival, overall survival, and assessing the treatment related 
complications associated with palliative radiation. As HIV/AIDS in South Africa is a 
prominent health concern, it should feature when larger local studies are being performed 
to ascertain if it is a prognostic factor in the palliation of locally advanced oesophageal 
cancer.  
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6. APPENDICES 
APPENDIX 1 
 
CHARLOTTE MAXEKE JOHANNESBURG ACADEMIC HOSPITAL  
DEPARTMENT OF RADIATION ONCOLOGY 
CARCINOMA OESOPHAGUS PROFORMA 
 
1. Code No.: ____ 
2. Age:  
3. Suitability:       
00. Suitable 
01. Not suitable 
 
4. Registration date:  
5. Age (years)  
 
6. Gender      
00- Male 
01- Female 
CLINICAL PRESENTATION    
7. Difficulty swallowing  
00- Not applicable 
01- Not known (5) 
02- Able to eat normal diet(0) 
03- Able to swallow some solids(1) 
04- Can swallow semi solids(2) 
05- Can swallow liquids(3) 
06- Total obstruction(4) 
8. Weight. Loss      
00- Not known 
01- Present 
02- Absent  
 
 If present        Kg 
 
 
 
DD / MM / YYYY 
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9. Other presentations    
00- Not applicable 
01- Not known 
02- Chest pain 
03- Hoarseness 
04- Back pain 
05- T.O.F. 
06- S/C node involvement 
07- Abdominal node involvement 
08- Liver involvement 
09- Combination 
10- Other (Specify) 
 
Period    months 
10. Habits      
00- None 
01- Smoking 
02- Drinking 
03- Both 
 
11. Performance status    
00- Not applicable 
01- Not known 
02- Fully active (ECOG0) 
03- Able to carry out work of a light nature (ECOG1) 
04- Capable of all self-care. Up and about >50% of waking hours (ECOG2) 
05- Capable of limited self-care, confined to bed or chair >50% of waking hours 
(ECOG3)  
06- Completely disabled. Totally confined to bed (ECOG4) 
 
Laboratory ASSESSMENT 
 
12. HB     (gms/100ml)  
 
13. WBC     (cu/mm)  
 
14. Albumin     (gms/ml)  
 
15. Alk. Phos    (U/L)  
 
16. HIV 
00- Not done 
01- Positive 
02- Negative. 
 
CD4 count   ARVs:  
 
Y/N 
38 
  
 
 
 
 
17. A. Barium swallow (Lesion length – cm) 
00- Not applicable 
01- Not known 
02- <5 cm 
03- 5-10 cm 
04- > 10 cm 
 
B. Vertebral height:  
 
      C.  Endoscopy, distance from incisor  
 
18. Site of lesion 
00- Not applicable 
01- Not known 
02- Upper 3rd 
03- Middle 3rd 
04- Lower 3rd 
05- Upper + mid 
06- Mid+ lower 
07- Whole length 
08- Lower  
19. Initial treatment     
00- Not applicable 
01- Not known 
02- No treatment 
03- Radiotherapy 
04- Other (Specify) 
20. Histological grade     
00- Not applicable 
01- Not known 
02- Well differentiated 
03- Moderately differentiated 
04- Poorly differentiated 
05- Undifferentiated 
06- No Grade 
 
21. Planned Radiotherapy    
 
00. Date of start     
       
 
      01. Date of completion:     
 
DD / MM / YYYY 
DD / MM / YYYY 
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22. Dosage schedule     
00- Not applicable 
01- Not known 
02- 30Gy/10fr/2 weeks EBRT 
03- 16Gy/2fr/2weeks ILBT 
04- 20Gy/5fr/1week EBRT 
05- 30Gy/10# + ILBT (16Gy/2fr) 
06- 20Gy/5# + ILBT (16Gy/2fr) 
     
 
23. Complications     
00- Not applicable 
01- Not known 
02- No complications 
03- Stricture 
04- Ulceration 
05- T.O.F. 
24. Immediate response    
00- Not applicable 
01- Not known 
02- Complete response 
03- Partial response(30%+) 
04- Poor response 
05- Progressive disease 
25. Site of recurrence 
00- Nil 
01- Local 
02- Loco regional 
03- Distant 
26. Response to treatment    
      00. Not applicable 
      01. Not known 
      02. Complete response 
      03. Partial response (30 %+) 
      04. Poor response 
 
 
27. Follow up swallowing (Swallowing score) 
      00. Able to eat normal diet (0) 
      01. Able to swallow some solids (1) 
      02. Can swallow semi solids (2)  
      03. Can swallow liquids (3) 
      04. Total obstruction (4) 
      05. Not known (5) 
40 
  
 
 
28. Time of relapse:  
 
      Months 
29. Disease free survival    
      00. Not applicable 
      01. Not known 
      02. Alive without disease 
      03. Died of other causes 
      04. Suffered relapse  
 
30. Overall Survival 
      Status      
      00. Not applicable 
      01. Not known 
      02. Alive 
      03. Died of disease  
 
31. Last follow up date 
 
32. Overall Survival (period) 
 
 
DD / MM / YYYY 
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